Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Continuous subcutaneous insulin infusion (CSII) therapy is currently accepted as a treatment strategy for type 1 diabetes. Transition from multiple daily injection therapy (MDI; including basal-bolus regimens) to CSII is based on expectations of better metabolic control and fewer hypoglycaemic events. Evidence to date has not been always conclusive. AREAS COVERED: Evidence for CSII and MDI in terms of glycaemic control, hypoglycaemia and psychosocial outcomes is reviewed in the adult and paediatric population with type 1 diabetes. Findings from studies on threshold-based insulin pump suspension and predictive low glucose management (PLGM) are outlined. Limitations of current CSII application and future technological developments are discussed. EXPERT OPINION: Glycaemic control and quality of life (QOL) may be improved by CSII compared to MDI depending on baseline HbA1c and hypoglycaemia rates. Future studies are expected to provide evidence on clinical and cost effectiveness in those who will benefit the most. Training, structured education and support are important to benefit from CSII. Novel technological approaches linking continuous glucose monitoring (CGM) and CSII may help mitigate against frequent hypoglycaemia in those at risk. Development of glucose-responsive automated closed-loop insulin delivery systems may reduce the burden of disease management and improve outcomes in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes
Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002853 · Cited by 894 · cited 2×
“[31] Adults and paediatrics Randomised parallel design Sensor-augmented pump therapy with rapid-acting insulin analogue Analoguebased basal bolus therapy 495 12 months Baseline mean HbA1c level (8.”
BackgroundLepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Threshold-based insulin-pump interruption for reduction of hypoglycemia
Bergenstal, R. M., Klonoff, D. C., Garg, S. K., Bode, B. W., Meredith, M., Slover, R. H., Ahmann, A. J., Welsh, J. B., Lee, S. W., & Kaufman, F. R. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1303576 · Cited by 652 · cited 1×
“hypoglycaemic events during the run-in phase.[53] The mean area under the curve for nocturnal hypoglycaemic events was lower by 37.”
BackgroundGlucose sensors: a review of current and emerging technology
Oliver, N. S., Toumazou, C., Cass, A. E. G., & Johnston, D. G. (2009) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02642.x · Cited by 584 · cited 1×
“new glucose readings every 1–5 min.[46] Comparative analyses of CGM in CSII versus MDI users are challenging as most studies included partici-”
MethodYeh, H.-C., Brown, T. T., Maruthur, N., Ranasinghe, P., Berger, Z., Suh, Y. D., Wilson, L. M., Haberl, E. B., Brick, J., Bass, E. B., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-5-201209040-00508 · Cited by 493 · cited 12×
“20)] and was comparable among adolescents >12 years and children <12 years.[41] A criticism of most comparative studies and meta-analyses is the inclusion of MDI participants not on a recommended analogue-based basal-bolus MDI regimen as comparator for CSII (see Table 1).”
BackgroundMethodInfluentialHome Use of an Artificial Beta Cell in Type 1 Diabetes
Thabit, H., Tauschmann, M., Allen, J. M., Leelarathna, L., Hartnell, S., Wilinska, M. E., Acerini, C. L., Dellweg, S., Benesch, C., Heinemann, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509351 · Cited by 450
Self-citationHeise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397 · cited 1×
“degludec has a prolonged half-life of 25 h, and clinical studies have shown a four-fold reduction in day-to-day within-subject pharmacodynamic variability, compared to insulin glargine.[11]”
BackgroundDoyle (Boland), E. A., Weinzimer, S. A., Steffen, A. T., Ahern, J. A. H., Vincent, M., & Tamborlane, W. V. (2004) · Diabetes Care · doi:10.2337/diacare.27.7.1554 · Cited by 373 · cited 1×
“[30] Paediatrics Randomised parallel design CSII therapy with rapid- acting insulin analogue Analoguebased basal bolus therapy 32 16 weeks HbA1c levels in the CSII group significantly decreased from 8.”
MethodHopkins, D., Lawrence, I., Mansell, P., Thompson, G., Amiel, S., Campbell, M., & Heller, S. (2012) · Diabetes Care · doi:10.2337/dc11-1579 · Cited by 265
(2015) · doi:10.1136/bmj.h3234 · Cited by 258
Cited by
Speight, J., Choudhary, P., Wilmot, E. G., Hendrieckx, C., Forde, H., Cheung, W. Y., Crabtree, T., Millar, B., Traviss‐Turner, G., Hill, A., et al. (2023) · Diabetic Medicine · doi:10.1111/dme.14944 · Cited by 92
Berg, A. K., Nørgaard, K., Thyssen, J. P., Zachariae, C., Hommel, E., Rytter, K., & Svensson, J. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0088 · Cited by 87
(2019) · doi:10.1089/dia.2018.0376 · Cited by 38
Taleb, N., Messier, V., Ott-Braschi, S., Ardilouze, J.-L., & Rabasa-Lhoret, R. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.07.035 · Cited by 25
Metadata
- Authors
- Thabit, H., & Hovorka, R.
- Venue
- Expert Opinion on Drug Delivery
- Publisher
- Informa Healthcare
- Published
- 2015-11-30
- Volume
- 13
- Issue
- 3
- Pages
- 389-400
- ISSN
- 1742-5247 (ISSN-L)
- 1744-7593
- OpenAlex
- W2189877335
- Cited by
- 58
- References
- 16
- FWCI
- 5.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. https://app.cochat.ai/papers/10.1517/17425247.2016.1115013
- The paper
- Thabit, H., & Hovorka, R. (2016). Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opinion on Drug Delivery. https://doi.org/10.1517/17425247.2016.1115013
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.